Destiny Pharma PLC Grant of Options (2340F)
October 25 2018 - 11:05AM
UK Regulatory
TIDMDEST
RNS Number : 2340F
Destiny Pharma PLC
25 October 2018
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY
THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER
THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF
THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Destiny Pharma plc
("Destiny Pharma" or the "Company")
Grant of Options
Brighton, United Kingdom - 25 October 2018 - Destiny Pharma
(AIM: DEST), a clinical stage biotechnology company focused on the
development of novel anti-microbial drugs, which address the global
problem of anti-microbial resistance (AMR), announces that it has
granted options ("Options") over 300,000 new ordinary shares of 1
pence each in the Company ("Ordinary Shares") (representing 0.69
per cent. of the Company's issued share capital) to Shaun Claydon,
the Company's new Chief Financial Officer who joined the board
after close of business yesterday. Mr. Claydon has no other options
over, or holdings in, the Company's shares.
The Options represent awards under the Destiny Pharma Employee
Long Term Incentive Plan 2018 approved by the Company on 25 January
2018 for EMI and non-tax advantaged options. 150,000 of the Options
have been granted at a price of 76.5 pence per Ordinary Share,
being the closing mid-market price of an Ordinary Share on 24
October 2018, which will vest on the third anniversary of the date
of grant and are exercisable for ten years thereafter. The
remainder of the Options have been granted at a price of 1 pence
each, of which, 50,000 will vest on 31 January 2019, 100,000 will
vest on 31 January 2020 and all will be exercisable for ten years
thereafter.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
pressoffice@destinypharma.com
+44 (0)1273 704 440
FTI Consulting
Simon Conway / Victoria Foster Mitchell
destinypharma@fticonsulting.com
+44 (0) 20 3727 1000
Cantor Fitzgerald Europe (Nominated Adviser and Joint
Broker)
Philip Davies / Will Goode, Corporate Finance
Andrew Keith, Healthcare Equity Sales
+44 (0)20 7894 7000
finnCap Ltd (Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative
biotechnology company focused on the development of novel medicines
that represent a new approach to the treatment of infectious
disease. These potential new medicines are being developed to
address the need for new drugs for the prevention and treatment of
life-threatening infections caused by antibiotic-resistant
bacteria, often referred to as "superbugs". Tackling anti-microbial
resistance has become a global imperative recognised by the World
Health Organisation (WHO) and the United Nations, as well as the G7
and the G20 countries. For further information, please visit
https://www.destinypharma.com
The notification set out below is provided in accordance with
the requirements of the EU Market Abuse Regulation.
1 Details of the relevant person / person closely associated
a) Name Shaun Claydon
----------------------------- --------------------------------
2 Reason for the notification
---------------------------------------------------------------
a) Position/status Chief Financial Officer
----------------------------- --------------------------------
b) Initial notification/ Initial notification
Amendment
----------------------------- --------------------------------
3 Details of the issuer
---------------------------------------------------------------
a) Name Destiny Pharma plc
----------------------------- --------------------------------
b) LEI 213800O9WH9Z38EHAC95
----------------------------- --------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii each type of transaction;
(iii each date; and (iv) each place where transactions have
been conducted
---------------------------------------------------------------
a) Description of the Options over Ordinary Shares
financial instrument,
type of instrument
Identification code GB00BDHSP575
----------------------------- --------------------------------
b) Nature of the transaction Grant of options
----------------------------- --------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
76.5 pence 150,000
----------
1 pence 50,000
----------
1 pence 150,000
----------
----------------------------- --------------------------------
d) Aggregated information
- Aggregated volume As above
- Price As above
----------------------------- --------------------------------
e) Date of the transaction 25 October 2018
----------------------------- --------------------------------
f) Place of the transaction AIM
----------------------------- --------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHLLFIEIFLEFIT
(END) Dow Jones Newswires
October 25, 2018 11:05 ET (15:05 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2024 to May 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From May 2023 to May 2024